Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc.

Bullboard Posts

Comment by Unicorn9000on Jul 06, 2020 10:45am

162 Views

Post# 31228392

RE:Dudes, I still have AGN on my watch list...

luvhorses wrote: can't see this moving until they have:
a) $$$ from Health CAnada; and/or

b) actual stats from the trials

Until then, it'll be on HOLD for me. Still funken peeved over mgmt handling of the financing for sure. AGN longs have yet to recover from it!!

then you are too late by then...

you anticipate when it happens...... End of July was there target for patient enrollment. I pretty sure we have about 50 enrolled already.

don't get left behind.............horses can't fly unicorns can.

scary stuff indeed

Bullboard Posts

NervGen Pharma: Proof that NVG-291 works?